Drug Trial Radar · NCT01511289
Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients
Last checked: Nov 19, 2026Latest source record: Feb 24, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
242
Actual
Start
Aug 2011
Primary completion
Feb 2015
Sponsor
- Lead sponsor
- Il-Yang Pharm. Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 18, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, the efficacy and safety of two radotinib doses, 300 mg twice daily and 400 mg twice daily, will be compared with imatinib 400 mg once daily in newly diagnosed patients with Philadelphia chromosome-positive (Ph+) Chronic Myelogenous Leukemia in the chronic phase (CML-CP).
Conditions
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Philadelphia Chromosome
- Bone Marrow Diseases
- Hematologic Diseases
Interventions
ImatinibDrug
400mg/Tab, QD
RadotinibDrug
100mg or 200mg/Capsule, 300mg or 400mg BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Major Molecular Response(MMR) by 12 monthsTime frame: 12 months
Locations
22 sites in 4 countries. Site status is shown where the registry gives one.
Local Institution
Jakarta, Indonesia
Local Institution
Batangas, Philippines
Local Institution
Manila, Philippines
Local Institution
Busan, South Korea
Local Institution
Busan, South Korea
Local Institution
Busan, South Korea
Local Institution
Daegu, South Korea
Local Institution
Daejeon, South Korea
Local Institution
Gyeonggi-do, South Korea
Local Institution
Gyeonggi-do, South Korea
Local Institution
Gyeonggi-do, South Korea
Local Institution
Incheon, South Korea
Local Institution
Jeollabuk-do, South Korea
Local Institution
Jeonnam, South Korea
Local Institution
Seoul, South Korea
Local Institution
Seoul, South Korea
Local Institution
Seoul, South Korea
Local Institution
Seoul, South Korea
Local Institution
Seoul, South Korea
Local Institution
Ulsan, South Korea
Local Institution
Wŏnju, South Korea
Local Institution
Bangkok, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.